Garrett M Brodeur MD

Pediatric Solid Tumor Oncology

Professor, Pediatrics, Perelman School of Medicine

Summary

Dr. Garrett Brodeur is a pediatric oncologist in Philadelphia, PA and is affiliated with Children's Hospital of Philadelphia (CHOP). He received his medical degree from Washington University in St. Louis School of Medicine and has been in practice for over 45 years. He specializes in pediatric solid tumor oncology and is experienced in neuroblastoma, cancer predisposition, and nanoparticle drug delivery. He has more than 300 publications and over 50,000 citings.

Distinguished Career Award American Society of Pediatric Hematology-Oncology, 2020
Chair, Pediatric Cancer Working Group American Association for Cancer Research, 2015-2017
Pitcher of Hope Award Alex's Lemonade Stand Foundation, 2015
Member Association of American Physicians, 2015
Lifetime Achievement Award Advances in Neuroblastoma Research Association, 2014
Member Interurban Clinical Club (founded by William Osler), 1997
Member Society for Pediatric Research, 1995
Alpha Omega Alpha Washington University School of Medicine, 1990
Pediatric Oncologist Award American Society of Clinical Oncology, 1990
Fellow American Association for the Advancement of Science
Join now to see all

PubMed

Update on Retinoblastoma Predisposition and Surveillance Recommendations for Children.
Junne Kamihara, Jaclyn Schienda, Rose B McGee, Danielle Novetsky Friedman, Surya P Rednam
Clinical Cancer Research. 2025-02-25
Update on Surveillance Guidelines in Emerging Wilms Tumor Predisposition Syndromes.
Jack J Brzezinski, Kerri D Becktell, Gaëlle Bougeard, Garrett M Brodeur, Lisa R Diller
Clinical Cancer Research. 2025-01-06
Update on Surveillance for Wilms Tumor and Hepatoblastoma in Beckwith-Wiedemann Syndrome and Other Predisposition Syndromes.
Jennifer M Kalish, Kerri D Becktell, Gaëlle Bougeard, Garrett M Brodeur, Lisa R Diller
Clinical Cancer Research. 2024-12-02

Four Penn Cancer Researchers Inducted as Fellows of the AACR AcademyMarch 10th, 2025
Pediatric Brain Cancer Is Rare. A CHOP Doctor Explains Why Some Kids Are More Vulnerable Than OthersSeptember 27th, 2022
CHOP Researchers Refine Experimental Prodrug Treatment of High-Risk NeuroblastomaMarch 14th, 2022
Join now to see all

Prodrugs targeting norepinephrine transporter for dual-selective therapy of refractory neuroblastomaCHILDREN'S HOSP OF PHILADELPHIA2020–2025
TRK Expression And Inhibition In Human NeuroblastomasNational Cancer Institute2008–2012
Molecular Genetic Analysis Of Human NeuroblastomaNational Cancer Institute2004–2012
Cancer Center Research Training ProgramNational Cancer Institute2005–2007
Neuroblastoma Biology And TherapyNational Cancer Institute2004–2007
Effect Of TRK Expression And Inhibition In NeuroblastomaNational Cancer Institute2004–2006
Cancer Research Training ProgramNational Cancer Institute1999–2004
Neuroblastoma Biology And TherapyNational Cancer Institute2003
Effect Of TRK Expression And Inhibition In NeuroblastomaNational Cancer Institute2002–2003
Molecular Genetic Analysis Of Human NeuroblastomaNational Cancer Institute1993–2003
Neurotrophin And TRK Expression In Medulloblastoma And NeuroblastomaNational Institute Of Neurological Disorders And Stroke1996–2000
Genetic Analysis Of Neuroblastoma PredipositionNational Center For Research Resources1996
Molecular Genetic Analysis Of NeuroblastomaNational Cancer Institute1996
Gordan Research Conference On Cancer INational Cancer Institute1992
Molecular Genetic Analysis Of Human NeuroblastomaNational Cancer Institute1985–1992
Molecular Genetic Analysis Of Human NeuroblastomaNational Cancer Institute1985–1989